ArticleJournal of controlled release : official journal of the Controlled Release Society2011
Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Liposomal DoxorubicinCurrent drug delivery · 2024Pooled it
- Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications.3 Biotech · 2024Review
- Review
- Harnessing molecular recognition for localized drug delivery.Advanced drug delivery reviews · 2021Review
- Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.Advanced therapeutics · 2021Review
- Evaluation of NanotargetedInternational journal of molecular sciences · 2021Article
- Review
- PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Enhancing Radiotherapeutic Effect With Nanoparticle-Mediated Radiosensitizer Delivery Guided By Focused Gamma Rays In Lewis Lung Carcinoma-Bearing Mouse Brain Tumor Models.International journal of nanomedicine · 2019Article
- In Vivo Translation of Peptide-Targeted Drug Delivery Systems Discovered by Phage Display.Bioconjugate chemistry · 2018Review
- The effects of doxorubicin-loaded liposomes on viability, stem cell surface marker expression and secretion of vascular endothelial growth factor of three-dimensional stem cell spheroids.Experimental and therapeutic medicine · 2018Article
- High-Throughput Approaches to the Development of Molecular Imaging Agents.Molecular imaging and biology · 2017Review
- Tumor-targeting peptides from combinatorial libraries.Advanced drug delivery reviews · 2017Review
- Phosphorylcholine-based stealthy nanocapsules enabling tumor microenvironment-responsive doxorubicin release for tumor suppression.Theranostics · 2017Article
- Article
- Chemically enhanced radiotherapy: visions for the future.Annals of translational medicine · 2016Review
- Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats.International journal of nanomedicine · 2016Article
- Radiation-Guided Peptide Delivery in a Mouse Model of Nasopharyngeal Carcinoma.BioMed research international · 2016Article
- Smart nanosystems: Bio-inspired technologies that interact with the host environment.Proceedings of the National Academy of Sciences of the United States of America · 2015Review
- Nanotechnology in radiation oncology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Tumor-targeted drug delivery improves anti-tumor efficacy and reduces systemic toxicity by limiting bioavailability of cytotoxic drugs to within tumors. Targeting reagents, such as peptides or antibodies recognizing molecular targets over-expressed within tumors, have been used to improve liposome-encapsulated drug accumulation within tumors and resulted in enhanced tumor growth control. In this report, we expand the scope of targeting reagents by showing that one peptide, HVGGSSV which was isolated from an in vivo screening of phage-displayed peptide library due to its selective binding within irradiated tumors, enabled highly selective tumor-targeted delivery of liposome-encapsulated doxorubicin and resulted in enhanced cytotoxicity within tumors. Targeting liposomes (TL) and non-targeting liposomes (nTL) were labeled with Alexa Fluor 750. Biodistribution of the liposomes within tumor-bearing mice was studied with near infrared (NIR) imaging. In the single dose pharmacokinetic study, the liposomal doxorubicin has an extended circulation half life as compared to the free doxorubicin. Targeting liposomes partitioned to the irradiated tumors and improved drug deposition and retention within tumors. The tumor-targeted delivery of doxorubicin improved tumor growth control as indicated with reduced tumor growth rate and tumor cell proliferation, enhanced tumor blood vessel destruction, and increased treatment-associated apoptosis and necrosis of tumor cells. Collectively, the results demonstrated the remarkable capability of the HVGGSSV peptide in radiation-guided drug delivery to tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.